H2-150 150 mg (Tablet)
Unit Price: ৳ 2.00 (100's pack: ৳ 200.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Apollo pharmaceutical ltd |
Title
- H2-150 Ranitidine Tablet & Syrup
Categories
- Medicine
- Gastrointestinal Health
Description
- Indicated in treatment of active duodenal ulcer, benign gastric ulcer, ulcer associated with non-steroidal anti-inflammatory agent, post operative stress ulcer, Zollinger-Ellison Syndrome, and Gastroesophageal reflux disease (GERD)
- Competitively blocks histamine at H2-receptors of the gastric parietal cells
- Dosage for duodenal and gastric ulcer, reflux oesophagitis, Zollinger Ellison syndrome, episodic dyspepsia, and maintenance
- Interacts with propantheline bromide, coumarin anticoagulants, theophylline, diazepam, propanolol, ketoconazole, midazolam, glipizide, and antacids
- Contraindicated in patients hypersensitive to Ranitidine
- Well tolerated with side effects such as altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, and muscle or joint pain being uncommon
- Crosses the placenta and excreted in human breast milk, caution advised in pregnancy and lactation
- Should be given in reduced dosage to patients with impaired renal and hepatic function
- Ulcer healing rates similar in elderly patients as in younger patients, with no difference in the incidence of adverse effects
- No particular problems expected following overdosage, symptomatic and supportive therapy recommended if required
- Belongs to therapeutic class H2 receptor antagonist
- Reconstitution guidelines for slow IV injection, intermittent slow IV infusion, continuous IV infusion, and for patients with Zollinger-Ellison syndrome or other hypersecretory conditions
- Should be stored in a cool and dry place, protected from light
Dimensions
Color Options
Functions
- Blocks histamine at H2-receptors of the gastric parietal cells
- Competitively inhibits gastric acid secretion
- Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin
Materials
- Ranitidine
Technical Specifications
- Dosage: 150 mg twice daily for duodenal and gastric ulcer, 150 mg twice daily for reflux oesophagitis, 150 mg 3 times daily for Zollinger Ellison syndrome, 150 mg twice daily for episodic dyspepsia, and 150 mg at night for maintenance
- Interactions: Delays absorption and increases peak serum concentration with propantheline bromide, minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam, and propanolol, alters absorption of pH-dependent drugs, and reduces bioavailability with antacids
- Contraindications: Hypersensitivity to Ranitidine
- Side Effects: Altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, and muscle or joint pain
- Pregnancy & Lactation: Crosses the placenta, excreted in human breast milk, caution advised in pregnancy and lactation
- Precautions & Warnings: Reduced dosage advised for patients with impaired renal and hepatic function
- Storage Conditions: Store in a cool and dry place, protect from light
Design Elements
Usability Features
Others
- Indicated in gastritis, ulcer prevention, and stress ulcer prevention
- May be given in reduced dosage to pediatric patients with impaired renal and hepatic function
- Recommended oral dose for the treatment of peptic ulcer in children is 2 mg/kg to 4 mg/kg twice daily, up to a maximum of 300 mg per day
- Symptomatic and supportive therapy recommended in case of overdosage
- No difference in ulcer healing rates and adverse effects observed between elderly and younger patients